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Hyperglycemia Causes Renal Cell Damage via
CCN2-Induced Activation of the TrkA Receptor
Implications for Diabetic Nephropathy
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CCN2, a secreted proﬁbrotic protein, is highly expressed in di-
abetic nephropathy (DN) and implicated in its pathogenesis;
however, the actions of CCN2 in DN remain elusive. We previously
demonstrated that CCN2 triggers signaling via tropomyosin re-
ceptor kinase A (TrkA). Trace expression of TrkA is found in
normal kidneys, but its expression is elevated in several nephrop-
athies; yet its role in DN is unexplored. In this study we show de
novo expression of TrkA in human and murine DN. We go on to
study the molecular mechanisms leading to TrkA activation and show
that it involves hypoxia, as demonstrated by ischemia–reperfusion
injury and in vitro experiments mimicking hypoxia, implicating
hypoxia as a common pathway leading to disease. We also ex-
pose renal cells to hyperglycemia, which led to TrkA phosphor-
ylation in mesangial cells, tubular epithelial cells, and podocytes
but not in glomerular endothelial cells and renal ﬁbroblasts. In
addition, we report that hyperglycemia caused an induction of
phosphorylated extracellular signal–related kinase 1/2 and Snail1
that was abrogated by silencing of TrkA or CCN2 using small
interfering RNA. In conclusion, we provide novel evidence that
TrkA is activated in diabetic kidneys and suggest that anti-TrkA
therapy may prove beneﬁcial in DN.Diabetes 61:2280–2288, 2012
Diabetic nephropathy (DN) is characterized by ex-cessive deposition of extracellular matrix (ECM)proteins in the mesangium. Mesangial expansionleads to obliteration of glomerular capillaries,
followed by tubulointerstitial ﬁbrosis and subsequent loss
of organ function (1). A main feature of kidney ﬁbrosis is
uncontrolled type I collagen deposition, which is triggered
by transforming growth factor-b (TGF-b) (2). High glucose
(HG) is involved in the pathogenesis of DN. It induces TGF-b
and connective tissue growth factor (CTGF, CCN2) in cul-
tured renal cells and in vivo (3–5). Previous work in our
laboratory showed that increased expression of CCN2
correlates with progression of human DN, as shown by in
situ hybridization and immunohistochemical analyses of
biopsy specimens from patients with different stages of DN
(6). CCN2 is also induced by TGF-b, hypoxia (low oxygen),
and advanced glycation-end products, all of which are
stimulants that result in kidney damage (6–9). Moreover,
CCN2 overexpression in transgenic mice with streptozotocin-
induced DN led to worsening of the disease, thus indicating
the latter may play a proﬁbrotic role after primary injury in
the context of diabetes (10).
More evidence that CCN2 is a proﬁbrotic protein comes
from studies of genetically modiﬁed animals. Sonnylal et al.
(11) showed that transgenic mice overexpressing CCN2 un-
der the collagen 1 a 2 promoter (COL1A2) showed a higher
susceptibility to carbon tetrachloride-induced liver ﬁbrosis.
In addition, mice with a ﬁbroblast/smooth muscle cell–
speciﬁc deletion of CCN2 were more resistant to bleomycin-
induced skin ﬁbrosis than wild-type controls (12).
Thus genetic evidence supports the idea that CCN2 may
be involved in driving ﬁbrogenesis in vivo (13). However,
we recently showed that the role of CCN2 during ﬁbrosis,
at least in the kidney, is more complex than previously
thought. We used transgenic CCN2 mice injured with
aristolochic acid, which targets kidney tubules and causes
tubular death and atrophy, followed by ﬁbrosis, and showed
that modest elevation of CCN2 expression did not correlate
with more kidney ﬁbrosis, suggesting that CCN2 effects are
highly dosage- and context-speciﬁc (14). Moreover, experi-
ments with CCN2 knockout mice demonstrated that CCN2
was not required for skin development (15), supporting the
importance of obtaining a clearer understanding of the role
of CCN2 in physiologic and pathologic situations, in order to
use this information to inform new therapeutic interventions.
CCN2 is secreted, and therefore to initiate cellular re-
sponses, it is thought to require interaction(s) with plasma
membrane receptors. We previously showed that CCN2
activated and coimmunoprecipitated with the tropomyosin
receptor kinase A (TrkA) in human mesangial cells (HMCs)
(16). TrkA was originally described as a transmembrane
receptor for the neurotrophin, nerve growth factor (17). We
showed that pharmacologic inhibition of TrkA inhibited CCN2-
stimulated signaling in mesangial cells, suggesting the receptor
may be essential for some CCN2-mediated effects (16). In
accord with this, pharmacologic inhibition of TrkA inhibited
CCN2-stimulated induction of monocyte-chemoattractant
protein-1 (MCP-1), fractalkine, regulated upon activation,
normal T-cell expressed, and secreted (RANTES), and
interlukin-8 (IL-8) in human renal cells (18,19). Moreover,
although only trace TrkA is expressed in normal kidneys, its
expression becomes prominent in human IgA nephropathy,
lupus nephritis, and glomerulonephritis (20,21). However,
the expression and activation of TrkA in DN is completely
unexplored.
Hypoxia is a well-established feature of the diabetic
kidney: the decreased bioavailability of nitric oxide leads to
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cytochrome c oxidase activation, which initiates mitochon-
drial respiration and results in O2 consumption (22). In
addition, sodium potassium ATPase activity is increased
during DN, and this is O2-dependent (23). Hypoxia-inducible
factor (HIF) is a transcriptional complex that responds to O2
changes; HIF is activated when O2 is low (23,24) and alters
transcription of target genes. Therefore, because the kid-
ney may be exposed to hypoxia during DN, we inves-
tigated whether low oxygen can activate the TrkA receptor
as part of a common pathway leading to end-stage renal
disease in diabetes.
RESEARCH DESIGN AND METHODS
Cell cultures, recombinant CCN2, and inhibitors. Human primary mesan-
gial, epithelial, and endothelial cells, purchased from Lonza and ScienCell Re-
search Laboratories, were cultured according to manufacturers’ instructions.
Transformed HMCs (tHMC) were described previously (4) and were grown
accordingly. A human podocyte line, grown at 33°C and differentiated at 37°C,
was a kind gift by Dr. M.A. Saleem (Bristol, U.K.) (25). TK173 renal ﬁbroblastic
line was a gift from Prof. F. Strutz (Gottingen, Germany), and primary human
renal ﬁbroblasts were from Dr. J. Norman (London, U.K.). HK2 cells were
purchased from American Type Culture Collection and grown according to
the manufacturer’s instructions. The tHMC cells were transfected 24 h after
seeding as previously described (2). An expression vector containing the CCN2
coding sequence was transfected into tHMC and supernatants were collected
(4). Human recombinant CCN2 was puriﬁed using Ni-NTA Magnetic Agarose
Beads (Qiagen) following the manufacturer’s instructions. HK2 cells were
treated with dimethyloxalylglycine (DMOG) (Frontier Scientiﬁc) or desfer-
rioxamine (DFO) (Sigma) 24–48 h before analysis for TrkA expression.
GW441756, a potent TrkA inhibitor (half-maximal inhibitory concentration = 2
nmol/L), was obtained from Axon Medchem (cat. no. Axon1251). A neutralizing
antibody to CCN2 was obtained from PeproTech and used according the man-
ufacturer’s instructions.
Western blotting and immunohistochemistry. Cells were lysed with
radioimmunoprecipitation assay lysis buffer supplemented with protease/
phosphatase inhibitors (Invitrogen). Protein concentration was estimated using
the BCA Protein Assay kit (Pierce) following the manufacturer’s instructions.
SDS-PAGE and transfer was done as previously described (2). The following
primary antibodies were used: rabbit polyclonal TrkA antibody (Upstate),
phospho-speciﬁc antibodies TrkA Tyr490 and Tyr674/675 (Cell Signaling
Technology and Santa Cruz), and CCN2, Snail, and phosphorylated extracel-
lular signal–related kinase (pERK; Santa Cruz). Detection was performed us-
ing the ECL Plus Detection System (Amersham Pharmacia Biotech), followed
by autoradiography. Cluster of differentiation 31 (CD31) was from Abcam
(ab28364). Immunohistochemistry was performed as previously described (14).
Scoring for Snail was performed using ImagePro software. CD31-positive glo-
merular cells were counted in 10 glomeruli per mouse and scores were plotted
as 3,3’-diaminobenzidine–positive cells.
Real-time RT-PCR. Total RNA was isolated using TRIzol (Invitrogen), and
2 mg total RNA was reverse transcribed using a one-step reverse transcription
kit (Roche). Speciﬁc primers for CCN2, TrkA, and b-actin were designed
(Primer 3 software) and purchased from Euroﬁns. Semiquantitative PCR was
performed using SYBR green reagent (Applied Biosystems) in an ABI real-time
PCR device in accordance with Applied Biosystems’ instructions. RNA was
retrieved from formalin-ﬁxed parafﬁn-embedded tissues from kidney biopsies
from three healthy control individuals and four patients diagnosed with DN.
Eight slices of 10-mm-thick sections were used for each RNA extraction. Re-
moval of wax was performed in a 1.5-mL tube with xylene/ethanol. RNA was
extracted in homogenized tissue using TRIzol reagent according to the man-
ufacturer’s instructions. Purity of RNA was determined by obtaining the 260-
to-280 ratio for each sample with NanoDrop ND-1000. Moreover, TrkA primers
span exons, lowering the potential of ampliﬁcation of genomic DNA. Fold
change was calculated using the comparative DDCT method.
Human tissues. The study was performed on histologic sections from biopsy
specimens that were surplus to those required for diagnostic purposes and was
approved by the Research Ethics Committee at the Hammersmith Hospital.
Human control kidney sections were purchased from ProSci Incorporated.
Animals. Heterozygote DBA/2-Ins2Akita mice and wild-type littermates were
purchased from The Jackson Laboratory (Bar Harbor, ME). Beginning at 8 weeks
of age, blood glucose was recorded at monthly intervals using a Glucometer
Optium Xceed (Pharmex). Blood samples were obtained by puncturing the tail
vein with a 21-gauge needle. Approximately 2 mL blood was collected directly
onto the testing strip for measurement. Urine was collected from mice that
were placed in individual metabolic cages for 24 h with free access to food and
water. Urinary creatinine concentration and albumin were measured using
the creatinine companion and an indirect competitive enzyme-linked im-
munosorbent assay according to the manufacturer’s instructions (Exocell,
Philadelphia, PA).
At age 22 weeks, mice were killed and their kidneys collected, decapsulated,
and incubated in formalin before they were embedded in parafﬁn. Sections
were stained with periodic acid–Schiff (PAS), hematoxylin-eosin (H&E), or
speciﬁc immunohistochemical staining for TrkA (Upstate) or CD31 (Abcam).
Ischemia–reperfusion injury was performed as described previously (26).
Brieﬂy, the left renal artery of mice under inhalation isoﬂurane anesthesia was
clamped with an atraumatic vascular clamp for 45 min, followed by reperfu-
sion for 24 h. The right uninjured kidney was used as a control in all experi-
ments. All mouse experiments were done under the authority of a U.K. Home
Ofﬁce license.
Statistical and bioinformatics analyses. Data were analyzed with GraphPad
Prism software with the one-way ANOVA test with the Bonferroni post hoc test.
Conservation between different species (with a human reference sequence)
was performed using Web-based genome browser, Vista (http://pipeline.lbl.gov/
cgi-bin/gateway2). The sequence of the TrkA promoter was analyzed for po-
tential binding hypoxia response elements (HRE) sites with Genomatix tran-
scription factor Web-based software (www.genomatix.de), and HRE were
conﬁrmed by manually searching for the “CGTG” motif within the promoter of
TrkA.
RESULTS
Diabetes drives TrkA expression in affected kidneys.
Experiments performed previously in our laboratory
identiﬁed CCN2 as a protein whose expression is signiﬁ-
cantly elevated in injured glomeruli during DN. Because
there was ambiguity about how CCN2, which is a secreted
cytokine, triggers intracellular signaling, our laboratory
discovered an interaction between CCN2 and TrkA that is
vital for ERK signaling via CCN2. In this study we decided
to investigate the expression of TrkA in kidneys from pa-
tients with established DN and compare this expression
with control tissue. Histologic examination of specimens
from ﬁve individuals with DN showed glycogen deposition,
casts, cellular inﬁltrate, and diffuse ﬁbrosis (Fig. 1A). Im-
munohistochemical detection of TrkA was performed, and
although we only detected trace TrkA in healthy human
tissue, TrkA was highly expressed in all of the specimens
of patients with DN that were studied (Fig. 1B, left panel).
The speciﬁcity of the antibody stained was conﬁrmed by
performing isotype control staining, which resulted in weak
staining (Fig. 1B, right panel). TrkA was expressed in tu-
bular epithelial cells and in glomerular cells of affected
kidneys. This is in accord with our previous ﬁnding that
CCN2 is expressed in injured glomeruli and may suggest
that released CCN2 activates TrkA and, via this, initiates
downstream signaling. TrkA expression was also checked
by real-time PCR, and we report that TrkA expression is low
in healthy human control (HC, n = 3) kidneys, whereas
TrkA mRNA expression is higher in patients with DN (n = 4)
compared with HC (Fig. 1C). The RNA absorbance 260-to-
280 ratio, which illustrates the purity of RNA, was 1.8 6
0.17. We then used a phospho-speciﬁc antibody to study
whether TrkA was activated by studying the phosphory-
lated form of TrkA. We report that TrkA was phosphorylated
(tyrosine Y490) in DN patients (Fig. 1D). Phosphorylation
of TrkA at Y490 is associated with initiating receptor sig-
naling through the ERK/mitogen-activated protein kinase
pathway (16).
After establishing that TrkA was activated in human DN,
we studied TrkA in a mouse model of DN. The previously
characterized DBA/2 mice, heterozygous for the insulin
2 (C96Y) mutation (Akita), were used for this (27,28). The
mice developed kidney disease, as illustrated by their
albumin-to-creatinine ratio of 91 6 21.3 for controls vs
370 6 81.3 for diabetic mice (P = 0.002). Strong tubular
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FIG. 1. Diabetes drives TrkA expression in affected kidneys. A: Five biopsy specimens of patients with DN (i) and tissues from human control indi-
viduals (ii) were stained with PAS; representative photomicrographs are shown.B: Immunohistochemistry for TrkAwas performed in all biopsy specimens
and representativemicrophotographs of DNand control tissue are shown.C: Real-time PCR for TrkA expression in specimens of tissues fromkidneys ofHC
patients (n=3)andDNpatients (n=4)wasperformed.Resultsare shownas foldchangenormalized tooneof theHCsamples.D: Phosphorylated formofTrkA
(Y490) was detected with speciﬁc antibody in DN but was not present, or barely detectable, in control specimens (blue-purple, hematoxylin counterstain of
nuclei; brown, speciﬁc stain of TrkA). E: A murine model of DN (DBA/2-Ins2Akita, lower panel) and DBA/2 control (upper panel) mice were probed immu-
nohistochemically for CD31 expression, a marker of endothelial cells (brown, CD31; blue-purple, hematoxylin nuclear counterstain) and for TrkA (brown,
TrkA; blue-purple, hematoxylin nuclear counterstain). Data for n = 6mice; representative photomicrographs are shown. The arrows indicate CD31-positive
cells in glomeruli; arrowheads indicate TrkA staining in tubules. F: CD31-postive glomerular cells were counted in control mice and compared with CD-31
positivity in glomeruli ofDNmice. The error bars inC andF show theSD. (Ahigh-quality digital representation of thisﬁgure is available in the online issue.)
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epithelial expression of TrkA was detected in diabetic but
not in control mice (Fig. 1E, left panel).
Because loss of endothelial cells has been reported dur-
ing DN (29), we studied the expression of CD31 (endothelial
cell marker) in glomeruli of DN and control mice. We report
that CD31 was expressed in glomeruli of control kidneys,
whereas diabetic mice showed a marked reduction in glo-
merular CD31-positive cells, suggestive of endothelial cell
death (Fig. 1E, right panel). Quantiﬁcation of numbers of
CD31-positive cells was performed (Fig. 1F). The expres-
sion of CD31 in renal cortical vessels (marking vascular
endothelial cells) did not change. The Akita mouse strain on
a DBA/2 genetic background became hyperglycemic early
on; however, we experienced problems with these mice
because they became sick and lost signiﬁcant weight, and
the experiment had to be terminated at age 6 months.
Therefore, using the Akita mouse strain on a DBA/2 back-
ground would be advisable if shorter-term glucose effects
are the main aim of the study.
HG-induced TrkA phosphorylation in mesangial cells
is CCN2-dependent.Having established that diabetes drives
TrkA expression in vivo, we decided to study this in vitro
using a model of hyperglycemia. We tested whether human
kidney primary and transformed cell lines express TrkA. We
report that TrkA is expressed in cultures of serum-starved
mesangial and proximal tubular epithelial cells, as well as in
podocytes, but is not expressed in renal ﬁbroblasts or renal
glomerular endothelial cells, as shown by mRNA and protein
(Fig. 2A and B, respectively). We then studied the effects of
glucose in mediating phosphorylation of TrkA (Y490). We ex-
posed cells to HG (30 mmol/L), low glucose (LG, 4 mmol/L),
or to an osmotic control (26 mmol/L sorbitol and 4 mmol/L
glucose). This did not alter total TrkA expression, as de-
termined by Western blotting; however, HG led to a signiﬁ-
cant increase of TrkA phosphorylation at positions Y490
(Fig. 2C) and Y674/675 (Fig. 2D). We also stimulated cells
with recombinant human CCN2 and recombinant nerve
growth factor as positive controls for the experiment (Fig.
2D). We report that CCN2 stimulated the receptor at Y490
to a similar level as that observed with HG stimulation (Fig.
2C); however, CCN2 led to more phosphorylation than
glucose at Y674/675, suggesting a dose-dependent activation
of the receptor (Fig. 2C and D, quantiﬁcation, lower panels).
We then investigated whether CCN2 is involved in the
HG-induced phosphorylation of TrkA. To study this, we si-
lenced CCN2 using speciﬁc small interfering RNA (siRNA)
sequences and found that in the absence of CCN2, HG failed
to induce phosphorylation of TrkA, suggesting that CCN2 is
required for this activation (Fig. 2C, CCN2 siRNA). HG also
failed to stimulate phosphorylation of TrkA in the presence
of a neutralizing antibody to CCN2 (Fig. 2E). To conﬁrm
that CCN2 was produced in response to HG stimulation,
we studied CCN2 production under LG and HG con-
centrations. We report that HG led to a time-dependent
upregulation of CCN2 mRNA and protein (Fig. 2F and G,
respectively), suggesting that some of the HG effects
can be attributed to CCN2 production. Collectively, we
conclude that HG led to TrkA phosphorylation in a
CCN2-dependent manner.
TrkA is required for HG-induced ERK phosphorylation
and Snail production. Isono et al. (30) reported that HG-
stimulated ERK1/2 activation led to TGF-b1 upregulation in
mesangial cells and contributed to increased extracellular
matrix expression. We conﬁrmed that HG induces phos-
phorylation of ERK1/2 in mesangial cells and, importantly,
showed that activation of ERK was inhibited by silencing
TrkA with siRNAs or pharmacologic inhibition (Fig. 3A) or
by inhibiting CCN2 with speciﬁc siRNA against CCN2 or a
neutralizing antibody to CCN2 (Fig. 3B). Scrambled siRNAs
had no effects on pERK or pTrkA status in mesangial cells
stimulated with HG or CCN2 (Fig. 3C). We thus propose
that activation of ERK1/2, in response to HG in HMCs
requires upregulation of CCN2 and activation of its receptor,
TrkA. HG stimulation led to a signiﬁcant upregulation of the
transcription factor Snail1, at the level of protein, in HK2
epithelial cells. The induction of Snail1 by HG was abro-
gated using selective silencing of TrkA (Fig. 3D, lower
panel), suggesting that HG induces Snail via activation of
the TrkA receptor pathway. Induction of Snail1 protein by
HG has not been reported previously; however, glucose-
depleted cancer cells undergo Snail1-dependent necrosis,
hence implicating Snail1 in metabolic stress-induced death
(31). Moreover, a previous study showed mRNA for Snail1
was induced by glucose in epithelial cells (32). We also
studied the expression of Snail1 in mesangial cells and
report it was below detection level in cells maintained in
LG or HG.
Hypoxia induces TrkA and may lead to kidney damage
in vivo. Hypoxia has been proposed to lead to accumulation
of extracellular matrix and ﬁbrosis. In the kidney, during DN,
it is suggested that certain regions are hypoxic. For this
reason, we hypothesized that a potential common pathway
that may lead to TrkA expression in vivo is hypoxia. Genes
that are upregulated by hypoxia have distinct consensus sites
on their promoters, HREs. HIF1a has been shown to interact
with HRE in relevant promoters to activate transcription
of the given gene. The classical HRE motif is 59-ACGTG-39.
Increased expression of HIF1a has been reported in
mesangial cells of diabetic mice (33).
To test whether TrkA contained HRE sites, we performed
bioinformatics analyses of the promoter of TrkA (i.e., up to
1.5 kb upstream of the transcriptional start site) using the
Vista genome browser and Genomatix Web-based tran-
scription factor software. We report that the TrkA pro-
moter contains four canonical HRE sites that are spread
within its promoter. The exact sites of the HREs are shown
schematically (Fig. 4A). We also studied the conservation
of base pairs between human (reference sequence), monkey
(Rhesus), dog, horse, mouse, rat, and chicken. This homol-
ogy search showed that the promoter of TrkA is highly
conserved between the human and the mouse, suggesting
the existence of important regulatory sequences (Fig. 4B)
that could be studied using a murine model.
We then went on to mimic the effects of low oxygen, using
small molecules, and studied the effects of hypoxia on TrkA
expression in human proximal tubular cells (HK2). TrkA is
expressed in serum-starved conditions, as previously shown
(Fig. 2A), but not in the presence of serum unless the cells
are otherwise challenged. HK2 cells, grown in 5% serum,
were exposed to DMOG, a cell-permeable, competitive in-
hibitor of HIF-a-prolyl hydroxylase (a stabilizer of HIF1)
(34), or DFO, an iron-chelator shown to induce HIF accu-
mulation (35), or DMSO as a negative control. Accumulation
of HIF1a with DMOG or DFO led to a signiﬁcant increase of
TrkA protein observed by Western blotting (Fig. 4C). These
data are quantiﬁed in Fig. 4D.
Having established that the TrkA promoter contains
sites for HIF1a binding that are conserved between the
human and the mouse, we then studied whether hypoxia
may lead to an increase of TrkA in vivo by performing
murine ischemia–reperfusion injury. As expected, normal
contralateral (uninjured) kidneys did not express TrkA;
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FIG. 2. HG-induced TrkA phosphorylation is CCN2-dependent. A: Real-time PCR was performed to detect TrkA mRNA in samples collected from
HMCs, human tubular epithelial cells (HK2), human renal transformed and differentiated podocytes (podocytes), human transformed renal
ﬁbroblasts (TK173), human primary renal ﬁbroblasts (ﬁbroblasts), and human primary glomerular endothelial cells (endothelial). Data are
expressed as fold change relative to expression of TrkA in podocytes (n = 5). Error bars show the SD. B: Western blot was performed to detect
TrkA protein expression in cells described; a representative blot is shown (n = 3). C: Phosphorylated (Y490) TrkA and actin loading control
protein expression was detected by Western blot in human primary mesangial cells; a representative blot is shown (n = 3). Quantiﬁcation of the
Western blot is shown (right-hand side panel). D: Phosphorylated TrkA at position Y674/675 was detected by Western blot and a representative
blot is shown (n = 3). Quantiﬁcation of the Western blot is shown (right-hand side panel). E: pTrkA was studied in LG and HG in the presence or
absence of neutralizing antibody. F: Real-time PCR was performed to detect CCN2 mRNA expression in mesangial cells in response to HG and LG
stimulation. Data are represented as fold change (n = 5). G: Western blot for CCN2 in HMC stimulated for increasing time with HG or LG or
sorbitol as the osmotic control (n = 3). (A high-quality color representation of this ﬁgure is available in the online issue.)
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FIG. 3. TrkA is required for HG-induced ERK phosphorylation and Snail production. A: Western blot analysis for pERK and total b-actin was
performed in mesangial cells treated with LG, sorbitol control, HG, or CCN2. TrkA was inhibited with speciﬁc siRNA or with pharmacologic in-
hibition (100 nmol/L GW441756). A representative blot is shown (n = 3). Quantiﬁcation of the Western blot is shown in the lower panel. B: Western
blot of pERK is shown for mesangial cells treated with different concentrations of glucose, or transfected with a CCN2 vector (V) alone, or to-
gether with CCN2 neutralizing antibody (Ab) treatment, or with silencing of CCN2 using a speciﬁc siRNA. A representative blot is shown (n = 3).
Quantiﬁcation of the Western blot is shown in the lower panel. C: Western blotting of pTrkA, pERK, and b-actin loading control in cells trans-
fected with nontargeting siRNA is shown. D: Snail1 immunoﬂuorescence was performed in HK2 cells using rabbit anti-Snail1 primary antibody
and anti-rabbit Cy3 conjugated secondary antibody (pink–red, Snail1; blue, DAPI nuclear counterstain). HG stimulated Snail1 production and
TrkA siRNA inhibited the HG-stimulated Snail1 expression. Representative photomicrographs are shown (n = 5). Scoring of Snail immuno-
ﬂuorescence is shown. The error bars indicate the SD. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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however, the kidneys that were subjected to hypoxia showed
damage that was associated with increased TrkA expres-
sion (Fig. 4E). The renal damage observed in these mice
is mainly localized in the tubules, as seen by tubular
dilatation and necrosis (Fig. 4E, PAS and H&E staining).
Consistent with tubular damage, the expression of TrkA
was also mainly localized in the tubules (Fig. 4E, brown
stain, TrkA; purple–blue, hematoxylin nuclear counter-
stain). In conclusion, these data indicate that TrkA is
a hypoxia-inducible gene that is upregulated in the kidney
by ischemia–reperfusion injury and in vitro by mimicking of
hypoxia.
DISCUSSION
TrkA is a member of the Trk family of plasma membrane
receptors (TrkA, TrkB, TrkC). These receptors interact
with neurotrophins, as homodimers or as heterodimers with
FIG. 4. Hypoxia induces TrkA and may lead to kidney damage in vivo. A: Bioinformatics analysis of the promoter of TrkA was performed and four
HRE sites were found and are diagrammatically presented. kb, kilobases; bp, base pairs. B: Vista Genome browser analysis was performed to ﬁnd
homology between the human and the mouse promoter sequence for TrkA. C: Western blot analysis for TrkA and b-actin was performed in HK2
cells treated with DFO or DMOG. Representative blot is shown (n = 4). D: Densitometry of TrkA protein expression was performed (n = 4).
E: A mouse model of ischemia–reperfusion was used to study the expression of TrkA in vivo. H&E and PAS were performed to assess renal damage
after ischemic injury. TrkA was detected, immunohistochemically, in ischemic kidneys but was absent in the contralateral control kidneys (right
side, brown stain; n = 5). UTR, untranslated regions. The error bars show the SD. (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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the pan neurotrophin receptor, p75NTR. Neurotrophins,
such as nerve growth factor, brain-derived neurotrophic
factor, neurotrophin 3 and 4, and their receptors, are critical
for the development, survival, and function of neurons (36).
Previous work performed in our laboratory has revealed
that mesangial cell TrkA was activated by CCN2 and co-
immunoprecipitated with it in crosslinking experiments
(16), suggesting a role for TrkA activation in the kidney.
Moreover, ephrin A5, another non-neurotrophin protein,
was found to interact with the TrkB receptor (37). There-
fore, it is evident that Trk receptors are also activated by
selected non-neurotrophin ligands in non-neuronal tissues,
perhaps implicating their involvement in other functions.
Our ﬁnding that TrkA is expressed in kidneys of DN
patients but not in healthy control subjects is important
because we previously showed that CCN2 is also markedly
increased in DN kidneys. Therefore, we put forward the
idea that HG induces CCN2 expression, which triggers
phosphorylation of TrkA and initiates intracellular signal-
ing that may result in ﬁbrosis. CCN2 exerts several actions
on mesangial cells in vitro that are likely to drive glo-
merulosclerosis in DN (7), and silencing of CCN2 in mice,
with the use of antisense oligonucleotides, ameliorates the
development of kidney changes in murine models of type 1
and 2 diabetes (38). Moreover, a polymorphism in the pro-
moter of CCN2 has been associated with scleroderma, a
condition that involves ﬁbrosis of multiple organs (39).
However, we recently showed that enhanced expression of
CCN2 in murine aristolochic acid nephropathy did not lead
to enhanced ﬁbrosis and postulated that this might be due
to dosage effects (14). Therefore, although the role of CCN2
in ﬁbrogenesis is established, new ﬁndings highlight the
importance of understanding how CCN2 interacts with other
molecules to initiate signaling. Our observation that TrkA
is expressed, although not activated, in several renal cell
types in LG culture conditions in vitro contrasts with in vivo
ﬁndings where it is not expressed in normoglycemic con-
trols. Because we established that TrkA expression in vivo
is upregulated in response to stressful conditions (e.g., hy-
perglycemia, hypoxia), it seems likely that the in vitro ex-
pression observed may be a response to stresses arising
from cell culture itself.
Our present study provides evidence for a pathway in
which HG causes cellular damage via TrkA, which is required
for the induction of the Snail1 transcription factor. Induction
of Snail is already implicated in metabolic stress conditions
because Snail is necessary for glucose depletion–induced
necrosis of cancer cells (31). Snail is a transcription factor
that is expressed in human ﬁbrotic but not in control
kidney tissue. Activation of Snail in adult transgenic mice
is sufﬁcient to induce tubular dilatation and kidney ﬁbrosis
(40). Although this was attributed to epithelial-mesenchymal
transition, a phenomenon known to be induced by Snail
in vitro, there is now debate about whether epithelial-
mesenchymal transition occurs in vivo (41). Thus, under-
standing the role of TrkA-induced Snail in vivo in HG
conditions is highly important and will require further
experimental work.
We report upregulation of TrkA in kidneys of a pre-
viously described murine model of DN (27,28). Mice with
the Akita mutation on a DBA/2 background had prolonged
hyperglycemia and proteinuria, in keeping with previously
published data (28). They lost weight and became sick early
on, requiring termination of the experimental protocol ear-
lier than anticipated. Histologic examination of the kidneys
revealed that there was no ﬁbrosis at this stage of disease;
however, there was marked proteinuria and mesangial ex-
pansion accompanied by endothelial cell loss as detected by
reduced expression of CD31, a marker of endothelial cells.
Loss of endothelial cells in human and rat DN is established
and is thought to be an important early pathogenic factor
leading to glomerular damage (29). It is of interest that TrkA
was already expressed in such kidneys, suggesting an early
involvement of TrkA in possibly driving some renal changes
before ﬁbrosis. Our in vivo studies on diabetic mice posed
the question about whether hyperglycemia may directly
stimulate TrkA in renal cells, and our in vitro experiments
shed light on this question by showing that HG led to TrkA
activation in a CCN2-dependent manner. Hence, we pro-
pose that TrkA may be one of the pathogenic factors in-
duced by HG and serves as a receptor for some of the
effects of CCN2.
The effects of HG in the kidney are multifactorial, and
TrkA represents one aspect of this series of events that
results in end-stage renal disease. In search for a common
pathway that may lead to a number of transcriptional changes
in the kidney that may cause damage, we investigated hy-
poxia. Hypoxia activates HIF transcription factors that alter
transcription of several target genes. We showed that TrkA
was activated by hypoxia not only in cells but also in vivo
using a mouse model of ischemia–reperfusion. Moreover,
because it is very likely that certain regions of the kidney
during DN become hypoxic early during disease develop-
ment, it is possible to hypothesize that hypoxia may be a
common pathway that leads to activation of TrkA, CCN2,
and other proteins that synergistically lead to tissue damage.
Therefore, inhibiting hypoxia-inducible factors and/or pre-
venting tissue hypoxia or some of the target molecules, such
as TrkA, may prove beneﬁcial in preventing kidney ﬁbrosis.
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